{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-098535","form_type":"8-K","ticker":"AKTX","cik":"0001541157","company_name":"Akari Therapeutics Plc","filed_at":"2024-08-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.458455+00:00","generated_at":"2026-05-31T08:40:09.812672+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Akari appoints Samir Patel as interim CEO; merger with Peak Bio on track for Q4 2024","bullets":["Samir R. Patel appointed interim CEO with employment contract consisting solely of equity compensation.","Merger with Peak Bio remains on track for Q4 2024 closing; combined entity to focus on ADC platform and PAS-nomacopan for GA.","Raised $7.6M in private placement and issued $1M in convertible notes to CEO and Chairman for operating capital.","Reported net loss of $7.6M for Q2 2024 vs $4.0M in Q2 2023; cash at $4.2M at June 30, 2024.","Received positive pre-IND feedback from FDA for PAS-nomacopan in geographic atrophy; IND filing planned for H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-098535","json":"https://secwatch.observer/filing/0000950170-24-098535.json","markdown":"https://secwatch.observer/filing/0000950170-24-098535.md","text":"https://secwatch.observer/filing/0000950170-24-098535.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024098535/0000950170-24-098535-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024098535/aktx-20240819.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T08:40:09.812672+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}